OBI Pharma, Inc. Statistics
OBI Pharma, Inc. (4174) Stock Statistics & Valuation Metrics
Total Valuation
OBI Pharma, Inc. has a market cap or net worth of TWD 6.38B. The enterprise value is TWD 4.62B.
- Market Cap
- TWD 6.38B
- Enterprise Value
- TWD 4.62B
Share Statistics
OBI Pharma, Inc. has 131,579,680 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 131,579,680
- Owned by Insiders
- ―
- Owned by Institutions
- 0.19%
Financial Efficiency
OBI Pharma, Inc.’s return on equity (ROE) is -1.09 and return on invested capital (ROIC) is -66.71%.
- Return on Equity (ROE)
- -1.09
- Return on Assets (ROA)
- -0.60
- Return on Invested Capital (ROIC)
- -66.71%
- Return on Capital Employed (ROCE)
- -0.71
- Revenue Per Employee
- 225.29K
- Profits Per Employee
- -7.90M
- Employee Count
- 260
- Asset Turnover
- 0.02
- Inventory Turnover
- 7.38
Valuation Ratios
The current PE Ratio of OBI Pharma, Inc. is -2.09. OBI Pharma, Inc.’s PEG ratio is 0.03.
- PE Ratio
- -2.09
- PS Ratio
- 143.67
- PB Ratio
- 5.04
- Price to FCF
- -4.84
- Price to Operating Cash Flow
- -4.90
- PEG Ratio
- 0.03
Income Statement
In the last 12 months, OBI Pharma, Inc. had revenue of 58.58M and earned -2.05B in profits. Earnings per share was -31.22.
- Revenue
- 58.58M
- Gross Profit
- -77.53M
- Operating Income
- -2.17B
- Pretax Income
- -2.26B
- Net Income
- -2.05B
- EBITDA
- -1.94B
- Earnings Per Share (EPS)
- -31.22
Cash Flow
In the last 12 months, operating cash flow was -1.53B and capital expenditures -20.83M, giving a free cash flow of -1.55B billion.
- Operating Cash Flow
- -1.53B
- Free Cash Flow
- -1.55B
- Free Cash Flow per Share
- -11.78
Dividends & Yields
OBI Pharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -22.05%
- Earnings Yield
- -21.72%
Stock Price Statistics
- Beta
- 0.21
- 52-Week Price Change
- 3.30%
- 50-Day Moving Average
- 40.51
- 200-Day Moving Average
- 35.28
- Relative Strength Index (RSI)
- 54.77
- Average Volume (3m)
- 1.02M
Important Dates
OBI Pharma, Inc. upcoming earnings date is Mar 15, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 30, 2026
- Next Earnings Date
- Mar 15, 2027
- Ex-Dividend Date
- ―
Financial Position
OBI Pharma, Inc. as a current ratio of 4.51, with Debt / Equity ratio of 27.31%
- Current Ratio
- 4.51
- Quick Ratio
- 4.45
- Debt to Market Cap
- 0.04
- Net Debt to EBITDA
- 0.13
- Interest Coverage Ratio
- -165.14
Taxes
In the past 12 months, OBI Pharma, Inc. has paid -2.73M in taxes.
- Income Tax
- -2.73M
- Effective Tax Rate
- 0.00
Enterprise Valuation
OBI Pharma, Inc. EV to EBITDA ratio is -5.18, with an EV/FCF ratio of -4.62.
- EV to Sales
- 137.14
- EV to EBITDA
- -5.18
- EV to Free Cash Flow
- -4.62
- EV to Operating Cash Flow
- -4.68
Balance Sheet
OBI Pharma, Inc. has TWD 496.96M in cash and marketable securities with TWD 446.14M in debt, giving a net cash position of TWD 50.82M billion.
- Cash & Marketable Securities
- TWD 496.96M
- Total Debt
- TWD 446.14M
- Net Cash
- TWD 50.82M
- Net Cash Per Share
- TWD 0.39
- Tangible Book Value Per Share
- TWD 16.39
Margins
Gross margin is -258.88%, with operating margin of -3139.94%, and net profit margin of -2922.86%.
- Gross Margin
- -258.88%
- Operating Margin
- -3139.94%
- Pretax Margin
- -3405.69%
- Net Profit Margin
- -2922.86%
- EBITDA Margin
- -2647.68%
- EBIT Margin
- -3088.65%
Analyst Forecast
The average price target for OBI Pharma, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -15.45%
- EPS Growth Forecast
- 23.86%
